Spectral flow cytometry panel identifies hematopoietic lineages in mouse bone marrow models
New lab method maps blood cell development in mice with high detail
A preclinical methodology study developed a 19-marker spectral flow cytometry panel for mouse bone marrow. The panel enabled simultaneous id…
A new lab method maps blood cell development in mice with high detail, letting scientists track the entire journey from stem cells to mature…
Imatinib reduces TNF-α levels in CML patients; persistent levels correlate with poor response
Imatinib treatment reduces inflammatory marker in CML patients in small study
A prospective observational cohort of 40 chronic-phase CML patients in India found imatinib significantly reduced serum TNF-α levels from 25…
Dropping inflammation markers in CML patients on imatinib treatment may help doctors predict who will respond well to the drug.
Retrospective US claims analysis examines complications in non-transfusion-dependent thalassemia
Study examines complications and treatments in adults with non-transfusion-dependent thalassemia
A retrospective observational cohort study of US adults with α- or β-non-transfusion-dependent thalassemia (NTDT) used claims data to examin…
Adults in the US with non-transfusion-dependent thalassemia face specific complications and treatment patterns that differ from matched cont…
Perspective highlights diagnostic overlap between idiopathic multicentric Castleman disease and systemic lupus erythematosus
Castleman disease can resemble lupus, requiring careful diagnosis for proper treatment
A perspective article discusses the clinical resemblance between idiopathic multicentric Castleman disease (iMCD) and systemic lupus erythem…
Castleman disease often mimics lupus with shared symptoms and autoantibodies, but misdiagnosis risks wrong treatment until a lymph node biop…
Case report describes management of Burkitt's lymphoma with concurrent HIV, CMV encephalitis, and salmonella bacteremia
Case report describes complex treatment for man with lymphoma, HIV, and infections
A case report describes a 50-year-old man with newly diagnosed HIV, stage IV Burkitt's lymphoma with CNS and marrow involvement, CMV viremia…
Doctors managed a 50-year-old man with newly diagnosed HIV, aggressive lymphoma, and multiple serious infections through coordinated care fr…
Phase III trial compares tisagenlecleucel to standard transplant in relapsed aggressive B-cell NHL
Can a one-time cell therapy beat standard treatment for aggressive lymphoma?
This randomized, open-label, multicenter phase III trial enrolled 322 adults with aggressive B-cell NHL relapsed/refractory within 1 year of…
A major trial compares one-time CAR-T cell therapy against standard chemo and stem cell transplant for aggressive lymphoma that returns quic…
Phase II trial compares quizartinib vs placebo with chemotherapy in FLT3 wild-type AML
Can adding quizartinib to standard chemo help adults with a common type of acute myeloid leukemia?
A randomized phase II trial compared standard chemotherapy plus quizartinib versus standard chemotherapy plus placebo in 273 adults with new…
Adding quizartinib to standard chemotherapy for newly diagnosed acute myeloid leukemia aims to help patients live longer without their cance…
Daratumumab + Len/Dex shows ORR in relapsed/refractory multiple myeloma phase 1/2 trial
Can a new drug combination help people with multiple myeloma that has returned after treatment?
This phase 1/2 study evaluated daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed-refracto…
A new three-drug combination of daratumumab, lenalidomide, and dexamasone showed safety and response in people with relapsed multiple myelom…
Phase I/II trial tests IMRT with chemotherapy before transplant for relapsed/refractory ALL/AML
Can a new radiation technique make stem cell transplants safer for leukemia?
A phase I/II trial record describes a study of intensity-modulated radiation therapy with etoposide and cyclophosphamide followed by allogen…
Doctors are testing a precise radiation technique to protect healthy organs while preparing patients for life-saving stem cell transplants.
Phase 2 trial explores idelalisib plus ofatumumab in untreated CLL/SLL requiring treatment
Can two drugs together help people with untreated blood cancer?
A phase 2 interventional trial evaluated idelalisib plus ofatumumab in 27 previously untreated CLL/SLL patients requiring therapy. The prima…
For people newly diagnosed with chronic lymphocytic leukemia or small lymphocytic lymphoma who need treatment, researchers tested a combinat…
Concizumab Reduces Bleeding in Hemophilia with Inhibitors: Median ABR 0.8 at 56 Weeks
Could a New Treatment Change the Lives of People with Hemophilia?
In the phase 3 explorer7 RCT, concizumab prophylaxis significantly reduced median annualized bleeding rate (ABR) to 0.8 in patients with hem…
A new treatment for hemophilia helped patients with inhibitors experience just one bleeding episode a year, offering hope for fewer interrup…
Phase II Trial: HST-NEETs Shows Promise in HIV-Associated Lymphoma Post-ASCT
Can a New Treatment Help Patients with HIV-Related Lymphoma Beat the Odds?
In a Phase II trial, HST-NEETs were administered post-ASCT in 12 patients with HIV-associated lymphoma. The study aimed to assess the feasib…
A new treatment combining immune therapy and bone marrow transplant aims to help patients with HIV-related lymphoma receive care sooner afte…